High cure rates with all-oral regimens for patients with HIV/hepatitis C virus (HCV) coinfection were a highlight of the 2015 Conference on Retroviruses and Opportunistic Infections. Twelve weeks of sofosbuvir and daclatasvir led to sustained virologic respons... ...
